Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in September:

The LD 500 Virtual Investor Conference
September 3, 2020 at 12:20 p.m. ET
Registration: https://www.webcaster4.com/Webcast/Page/2019/36780 

H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020
September 16, 2020 at 1:30 p.m. ET
Registration: https://www.meetmax.com/sched/event_61861/investor_login.html?attendee_role_id=INVESTOR  

Sidoti & Company 2020 Fall Virtual Investor Conference
September 23, 2020 at 2:30 p.m. ET
Registration: https://sidoti.meetmax.com/sched/event_63793/conference_register.html?attendee_role_id=SIDOTI_INVESTOR 

Management will be available for 1x1 meetings with investors throughout each event. Please contact your conference representative to schedule a meeting. To stay up to date on upcoming events please check our calendar regularly: https://ir.hoththerapeutics.com/events/category/events/

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please click here.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com 
www.hoththerapeutics.com
Phone: (678) 570-6791  

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-participation-at-upcoming-investor-conferences-in-september-301120459.html

SOURCE Hoth Therapeutics, Inc.